Foresite Capital Buys $25M Stake in Cytokinetics

Institutional investor takes major position in biopharmaceutical company

Mar. 16, 2026 at 10:05am

Got story updates? Submit your updates here. ›

Foresite Capital Management IV LLC, an institutional investor, has purchased a new stake of 458,295 shares in Cytokinetics, Incorporated (NASDAQ:CYTK), a biopharmaceutical company focused on developing novel treatments for muscle diseases. The stake is valued at approximately $25.2 million, making it Foresite Capital's second-largest holding.

Why it matters

This significant investment by a major institutional investor signals confidence in Cytokinetics' pipeline and future growth potential. As a late-stage biopharmaceutical company, Cytokinetics' success could have broader implications for the muscle disease treatment landscape.

The details

According to a recent SEC filing, Foresite Capital Management IV LLC purchased the 458,295 shares of Cytokinetics in the third quarter. This stake represents approximately 0.37% of the company's outstanding shares. Cytokinetics is focused on developing small-molecule therapeutics that modulate muscle function, with its lead program, omecamtiv mecarbil, being evaluated for the treatment of heart failure.

  • Foresite Capital purchased the Cytokinetics shares in the third quarter of 2026.

The players

Foresite Capital Management IV LLC

An institutional investment firm that has taken a major stake in Cytokinetics, Incorporated.

Cytokinetics, Incorporated

A late-stage biopharmaceutical company focused on developing novel treatments for muscle diseases, including heart failure.

Got photos? Submit your photos here. ›

The takeaway

This significant investment by Foresite Capital underscores the potential of Cytokinetics' pipeline and the growing interest in innovative muscle disease treatments. As Cytokinetics continues to advance its programs, this influx of capital could help accelerate its research and development efforts.